Oxaliplatin-Associated Amaurosis Fugax

Case Rep Oncol. 2021 Jun 11;14(2):832-837. doi: 10.1159/000516271. eCollection 2021 May-Aug.


Oxaliplatin-associated amaurosis fugax has not been reported, and its clinical course and treatment remain largely unclear. A 70-year-old man with advanced gastric cancer was treated with the SOX regimen. After cycle 1 of oxaliplatin infusion, the patient realized that his right eye had visual field impairment, which he described as darkening of the right half of his visual field and loss of vision lasting about 1 min and occurring about 7 times a day. The daily frequency of this occurrence gradually decreased, and his visual field impairment improved in 1 week. However, as the same symptoms recurred from cycle 2 to cycle 5 of treatment, oxaliplatin was discontinued from cycle 6 and switched to S-1 monotherapy. Subsequently, the patient's amaurosis fugax improved. To our knowledge, this is the first report describing clinical course and treatment of oxaliplatin-associated amaurosis fugax.

Keywords: Amaurosis fugax; Ocular toxicity; Oxaliplatin; S-1 + oxaliplatin.

Publication types

  • Case Reports